Cencora, Inc. (COR) Stock Forecast Oct. 14, 2026
Analysis updated on Oct. 14, 2026 (UTC) · Total · absolute moveSwitch to Alpha · NYSE
Cencora, Inc. (COR) stock forecast summary
On Oct. 14, 2026, COR is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 4009 stocks scored that day.
Cencora, Inc. is a large-cap company with a market capitalization of $62.99B. It ranks number 2 by market capitalization among the 6 Wholesale-Drugs, Proprietaries & Druggists' Sundries issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for COR is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +4.5%, buy ≥ +3.4%, sell < +2.1%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, COR included.
Follow COR freeCOR price chart and AI forecast
How COR ranks among 4009 stocks
90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Cencora, Inc. (COR) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Wholesale-Drugs, Proprietaries & Druggists' Sundries peers listed below that report each metric.
Valuation & Market
| Metric | COR | Rank |
|---|---|---|
| Market Cap | $62.99B | 2/6 |
| P/E Ratio | 24.00x | – |
| P/B Ratio | 20.65x | – |
| Dividend Yield | 0.74% | – |
| EPS | $13.47 | – |
| Book Value/Share | $15.99 | – |
| Revenue/Share | $1743.84 | – |
| FCF/Share | $21.28 | – |
Profitability & Margins
| Metric | COR | Rank |
|---|---|---|
| ROE | 86.0% | – |
| ROA | 3.1% | 4/8 |
| ROIC | 12.4% | 4/6 |
| Gross Margin | 4.0% | 5/7 |
| Operating Margin | 0.9% | 3/7 |
| Net Margin | 0.8% | 3/8 |
| EBT Margin | 1.1% | 3/8 |
| Tax Rate | 26.8% | – |
Financial Health
| Metric | COR | Rank |
|---|---|---|
| Current Ratio | 0.93x | 5/7 |
| Quick Ratio | 0.58x | 5/7 |
| D/E Ratio | 26.41x | – |
| Financial Leverage | 27.47x | – |
| Interest Coverage | 0.1x | 5/7 |
| Working Capital | -$3.86B | 6/7 |
Cash Flow
| Metric | COR | Rank |
|---|---|---|
| Operating Cash Flow | $4.82B | 3/8 |
| Free Cash Flow | $4.06B | 2/5 |
| Capital Spending | -$761M | 5/5 |
| OCF Growth YoY | 176.7% | 1/5 |
| FCF Growth YoY | 255.7% | – |
| FCF/Sales | 1.2% | 3/5 |
| CapEx/Sales | 0.2% | 4/5 |
Operational Efficiency
| Metric | COR | Rank |
|---|---|---|
| Asset Turnover | 3.97x | 2/5 |
| Receivables Turnover | 13.1x | 5/5 |
| Inventory Turnover | 15.2x | 2/7 |
| Fixed Assets Turnover | 117.2x | 2/5 |
| Days Sales Outstanding | 28 days | 1/5 |
| Days Inventory | 24 days | 6/7 |
| Payables Period | 62 days | 3/6 |
| Cash Conversion Cycle | -11 days | – |
Income Statement
| Metric | COR | Rank |
|---|---|---|
| Total Revenue | $332.77B | 2/5 |
| Operating Income | $3.04B | 2/7 |
| Net Income | $2.62B | 2/8 |
| SG&A Expense | $7.65B | 2/6 |
| Cost of Goods Sold | $319.55B | 2/8 |
Dividend & Shareholder Information
| Metric | COR | Rank |
|---|---|---|
| Dividends Per Share | $2.45 | – |
| Payout Ratio | 18.2% | – |
| Shares Outstanding | 191M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $55.34B | 66.0% of assets |
| Cash & Short-term Investments | $2.82B | 3.4% of assets |
| Accounts Receivable | $25.45B | 30.4% of assets |
| Inventory | $21.03B | 25.1% of assets |
| Total Liabilities | $80.57B | 96.1% of assets |
| Short-term Debt | $4.50B | 5.4% of assets |
COR quarterly financials and insider trading
Cencora, Inc. (COR) industry peers
Companies classified under the same SEC industry code as Cencora, Inc. (Wholesale-Drugs, Proprietaries & Druggists' Sundries): 8 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up freeWhere COR sits on the market map
Cencora, Inc. (COR) stock news
Loading...
Cencora, Inc. (COR) stock forecast FAQ
What is the Cencora, Inc. (COR) stock forecast?
On Oct. 14, 2026, COR is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 4009 stocks scored that day.
How accurate are Cencora, Inc. stock predictions?
A per-ticker accuracy statistic for COR is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Cencora, Inc. forecasts updated?
Cencora, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 14, 2026.
Which companies are Cencora, Inc.'s industry peers?
8 issuers in our coverage, COR included, share the SEC industry code Wholesale-Drugs, Proprietaries & Druggists' Sundries. The largest are: Mckesson Corp (MCK), Cardinal Health Inc (CAH), Herbalife Ltd. (HLF), Nu Skin Enterprises, Inc. (NUS), Hwh International Inc. (ESYN), Cosmos Health Inc. (COSM).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.